Navigation Links
New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR
Date:5/9/2008

Grunenthal licensed marketing rights to tapentadol to Ortho-McNeil-Janssen Pharmaceuticals, Inc. for the United States, Canada and Japan. Grunenthal maintains marketing rights in Europe and other parts of the world. A trade name for the product has not yet been determined.

[This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Company's Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are available online at http://www.sec.gov, http://www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.]

Media inquiries:

Greg Panico

+1 908-240-2011

+1 908-927-3715

Investor Relations inquiries:

Louise Mehrotra

+1 732-524-6491

Lesley Fishman

+1 732-524-3922


'/>"/>
SOURCE Johnson & Johnson Pharmaceutical Research & Development,L.L.C.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery
2. New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients
3. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
4. Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals
5. Data from Randomized Pilot Study, Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008
6. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
7. Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
8. Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents
9. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
10. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery
11. New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... , March 31, 2015  On May ... will convene in Santa Monica, CA ... on Lung-Sparing Therapies for Malignant Pleural Mesothelioma (MPM), ... exposure to asbestos and commonly affects the lining ... co-hosted by UCLA and the Pacific Mesothelioma Center ...
(Date:3/31/2015)... March 31, 2015 /CNW/ - T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" ... premium quality medical marijuana products and a licensed producer ... Purposes Regulations ( Canada ) ("MMPR"), is ... The Corporation of the District of Saanich ... Company,s premises which now allows for commercial distribution of ...
(Date:3/31/2015)... ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP ... 225mg and 300mg oral tablets, indicated for use in ... for Propafenone Hydrochloride 150mg, 225mg and 300mg tablets was ... Arthur S. Przybyl , President and Chief Executive ... of our fourth product from the portfolio of approved ...
Breaking Medicine Technology:Cutting-Edge Research to Be Presented at 5th Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma in Santa Monica 2Cutting-Edge Research to Be Presented at 5th Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma in Santa Monica 3Cutting-Edge Research to Be Presented at 5th Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma in Santa Monica 4T-Bird Pharma Inc. Announces Final Municipal Rezoning Approval 2T-Bird Pharma Inc. Announces Final Municipal Rezoning Approval 3ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 2ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 3
... Calif., Oct. 28 Although Breast Cancer Awareness Month is coming ... health is important throughout the year. What,s more, women age ... their potential risk for breast cancer. Based on the same ... the only FDA-cleared risk assessment tool for non-hereditary breast cancer. ...
... HOERSHOLM, Denmark and SAN DIEGO, California, October ... Mark Wedel, MD, FACP Joins as Vice President and Chief,Medical ... , - Stuart Mackey, JD joins ... Business Development for Proprietary RNA-targeted,Locked Nucleic Acid (LNA) Drug Platform ...
Cached Medicine Technology:Breast Health is a Year-Round Priority: New Technology Identifies Risk of Breast Cancer in Younger Women 2Breast Health is a Year-Round Priority: New Technology Identifies Risk of Breast Cancer in Younger Women 3Santaris Pharma A/S Expands Executive Team, Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA-targeted Drug Development Programs 2Santaris Pharma A/S Expands Executive Team, Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA-targeted Drug Development Programs 3Santaris Pharma A/S Expands Executive Team, Appoints Chief Medical Officer and Chief Business Officer to Advance Proprietary RNA-targeted Drug Development Programs 4
(Date:3/31/2015)... 31, 2015 Indosoft, Inc., developers of ... the availability of SIP over TCP configuration for all SIP ... offering a full contact center ACD (Automatic Call ... Adding SIP over TCP support to all SIP devices gives ... The history of Voice over IP (VoIP) has primarily involved ...
(Date:3/31/2015)... Exton, PA (PRWEB) March 31, 2015 ... to the physical, social and psychological benefits of ... about the thousands of adaptive sports athletes that ... United States, encourage support for inclusive fitness and ... individuals interested in participating in adaptive sports and ...
(Date:3/31/2015)... 31, 2015 Array Health , ... has announced that Lance Hood, Senior Director of Marketing, ... Exchange Forum on April 1, 2015. The session, co-presented ... will address how employers can streamline and simplify the ... WHAT: “ Optimizing Employee and Employer Needs in a ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 With intravenous ... vein using a catheter. Patients, typically, are prescribed IV ... that oral medications are no longer effective. Illness ... needed to help with electrolyte imbalances. Infusion therapy ... illness. In addition to treating dehydration, IV infusion therapy ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 The ... Health Care Administrators (ACHCA) elected two administrators from ... and long-term care in New Jersey, to two ... of new officers. Robert Reyes, administrator for Abingdon ... elected president, and Yael Herman, administrator of Canterbury ...
Breaking Medicine News(10 mins):Health News:Indosoft extends SIP over TCP support to User Extensions in its Q-Suite 5.9 Call Center Software 2Health News:April is National Adaptive Sports Month 2Health News:April is National Adaptive Sports Month 3Health News:Array Health’s Senior Director of Marketing to Co-Present with Benaissance at The Institute for HealthCare Consumerism Private Exchange Forum 2Health News:Intravenous Infusion Therapy Now Available at Urgent Care of Texas Centers; Hospital-Level Care in an Outpatient Setting. 2Health News:Abingdon Care & Rehabilitation Center’s Administrator Elected President of N.J. Chapter of the American College of Health Care Administrators 2
... study by Ceylan, from Turkey evaluated their experience in ... ,Their patient's ages ranged from 5 months to 24 ... circumcisions were performed at various centers or during religious ... ,The group found that the most commonly observed complication ...
... chemicals and industrial effluents in sea and soil could increase your ... was thought to be the most important factor in the development ... does not produce enough insulin - necessary for the body to ... South Korean researchers has shown that people whose bodies are polluted ...
... a lifetime.” , - Herbert Ward //, Child Abuse-The Bitter ... her imaginative world of fairies and angels, while her mom eked ... door jolted her out of her joyous reverie. She hastened to ... in disguise. He locked the door and raped her repeatedly. ...
... and Levitra are the answer to their prayers. But, ... report from Harvard Medical School, these pills offer no ... frequently accompany erectile dysfunction (ED). ,For one ... feeling sexual desire for his partner. If emotional issues ...
... already pressured hospital system would struggle to cope under ... a large-scale emergency, say trauma and emergency specialists.// ... targets for Australasian hospitals, says Dr Anthony Joseph, Director ... ,In the latest Medical Journal of Australia ...
... recently has shown that students who participate in sexual ... those who did not participate in the program. The ... desired positive impact. ,Critics have always ... the Federal government annually on the ‘abstinence-until-marriage education’may not ...
Cached Medicine News:Health News:Child Abuse - When God’s Gifts Land in Devils’ Clutch 2Health News:Child Abuse - When God’s Gifts Land in Devils’ Clutch 3Health News:Can Our Hospitals Cope In A Disaster? 2
... Oncor brings together Siemens existing patented ... MLC, and Virtual Wedge, with the ... workflow, patient position offset determination, and ... provide maximum efficiency of treatment delivery ...
The Primus linear accelerator is a fully digital, technologically advanced radiation therapy treatment delivery system. It can be configured for delivery of routine, 3-D conformal or IMRT treatments....
... EX accelerators are true ... Varian multileaf collimation and ... which enable you to ... computer-driven IMRT treatments, as ...
... Clinac EX accelerators are ... integrated Varian multileaf collimation ... systems which enable you ... advanced computer-driven IMRT treatments, ...
Medicine Products: